NEALS
Our Mission
Our mission is to translate scientific advances into new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND) as rapidly as possible.
To achieve our goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for ALS community. Learn more about our structure.
Our Values
The NEALS consortium is committed to the principles of open scientific communication, peer review, full and open disclosure of potential conflicts of interest, and democratic governance of its organization and activities.
History
NEALS was founded in 1995 with 9 academic clinical centers in the New England area. With help from The ALS Association’s TREAT ALS Network, Muscular Dystrophy Association, and our generous donors, the NEALS membership has grown to over 100 research centers committed to performing research in ALS and MND.
Phase 2 Trial Of AP-101 In SOD1 And Sporadic ALS
VirtualIn this webinar, Dr. Angela Genge will discuss the research behind AP-10l and provide an overview of the trial and what study participation involves. The phase 2 trial of AP-101 is currently enrolling participants with Familial Amyotrophic Lateral Sclerosis and Sporadic Amyotrophic Lateral Sclerosis.
NEALS Webinar: An Update on Tofersen
Tuesday, March 28, 2023 12:30 PM ET Please join us for a webinar update on tofersen moderated by NEALS Co-Chair Dr. Jinsy Andrews. Dr. Timothy Miller will provide background on tofersen and updates from the March 22nd FDA Advisory Committee Meeting. Holly Fernandez Lynch, an expert in FDA pharmaceutical policy and regulatory standards, will be […]
NEALS Webinar: Tofersen Update
NEALS Webinar: Tofersen Update Tuesday, May 2, 2023 4:00 PM ET The U.S. Food and Drug Administration (FDA) has granted accelerated approval for tofersen for the treatment of individuals with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Join Dr. Timothy Miller for a webinar update following the FDA’s recent announcement moderated by NEALS […]
Understanding Statistical and Clinical Significance
Presenters: Dr. Jinsy Andrews (Columbia University), Dr. Christina Fournier (Emory University), Dr. Eric Macklin (Mass General Hospital) What do researchers and scientists mean when they describe a study as “statistically significant?” How do people with ALS and clinicians understand whether or not a treatment option is “clinically significant?” Join us for a webinar and panel […]
22nd Annual NEALS Meeting
2023 Annual NEALS Meeting The 22nd Annual NEALS Meeting will be held October 4 - 6, 2023. Please check back in late Spring for additional details, including information on virtual options.
National ALS Registry: Learn How You Can Join the Fight Against ALS Confirmation
ZoomThe National ALS Registry is a multi-faceted research platform. Launched in 2010, the Registry evaluates the public health burden of ALS by determining who has ALS in the United States as well as investigating the causes and risk factors for this disease. The Registry also connects persons with ALS with clinical trials and epidemiological studies, […]
Bridging the Gap: The Crucial Role of Collaborative Pre-Clinical Research
VirtualTuesday, February 13, 2024 4:00 - 5:00 PM ET Please join us for a conversation with Dr. Christine Vande Velde (Robert Packard Center for ALS Research), Erin Fleming (Project ALS), and Dr. Fernando Vieira (ALS Therapy Development Institute) as we explore the role of the ALS community in shaping pre-clinical research, and the transformative impact […]